[go: up one dir, main page]

AR049335A1 - Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central - Google Patents

Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central

Info

Publication number
AR049335A1
AR049335A1 ARP050101667A ARP050101667A AR049335A1 AR 049335 A1 AR049335 A1 AR 049335A1 AR P050101667 A ARP050101667 A AR P050101667A AR P050101667 A ARP050101667 A AR P050101667A AR 049335 A1 AR049335 A1 AR 049335A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
aryl
con
heterocycle
Prior art date
Application number
ARP050101667A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049335(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR049335A1 publication Critical patent/AR049335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), y sales o derivados farmacéuticamente aceptables del mismo, donde: A es O o S; X es arilo, un heterociclo biciclo benzocondensado, -alquiloC1-10, -alqueniloC2-8, -cicloalquiloC5-8, -(CH2)n- cicloalquiloC3-9, cicloalquilo condensado, H, SCF3, hidroxi-alquiloC1-6, -alcoxiC1-6, -alcoxiC1-6-alcoxiC1-6, -(CH2)nS-alquiloC1-6, -(CH2)nSO2-alquiloC1-6; donde cada grupo está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre -alquiloC1-6, -cicloalquiloC3-8, -alcoxiC1-6, arilo, heterociclo, OH, halo, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, -CON(H)alquiloC1-6, -CON(alquiloC1-6)2, hidroxi-alquiloC1-6, -alcoxiC1-4, - SCF3, SO2, -alquilC1-4-S-alquiloC1-4, -alquilC1-4-S-, -alquilC1-4-NR'R'', NR'R'', con la condicion de que cuando X sea fenilo, fenilo sustituido, alquilo C1-4 no sustituido, alquilo C1-4 sustituido con halo, cicloalquilo C3-8 no sustituido o cicloalquilo C3-8 sustituido con halo, entonces * y @ sean (R,S) o (S,R); R1-R5 se seleccionan independientemente entre H, -alquiloC1-6, arilo, -cicloalquiloC3-8, -alqueniloC1-6, cicloalquenilo C5-8, -(CH2)ncicloalquiloC3-8, -alcoxiC1-6, -O-arilo, heterociclo, SO2, OH, halo, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, -CON(H)alquiloC1-6, -CON(alquiloC1-6)2, hidroxi-alquiloC1-6, -alcoxiC1-4-alquiloC1-6, -SCF3, -alquilC1-6-SO2, -alquilC1-4-S-alquiloC1-4, -alquilC1-4-S-, alquilC1-4-NR'R'' y NR'R'' y cuando dos de los grupos R1-R5 se unen al anillo pueden formar un anillo bicíclico benzocondensado que comprende un grupo fenilo condensado con un anillo carbocíclico de 5 o 6 miembros o un grupo fenilo condensado con un grupo heterocíclico de 5 o 6 miembros que contiene al menos un heteroátomo N, O o S y donde cada uno de los grupos -alquiloC1-6, arilo, -cicloalquiloC3-8, -alqueniloC2-8, -cicloalquenilo C5-8, -alcoxiC1-6, -heterociclo puede estar opcionalmente sustituido con uno o más de los siguientes grupos: arilo, heterociclo, OH, halo, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, -CON(H)alquiloC1-6, -CON(alquilC1-6)2, hidroxi-alquiloC1-6, alcoxi C1-6, alquilo C1-6, -SCF3, - alquilC1-6-SO2, -alquilC1-4-S-alquiloC1-4-, -alquilC1-4-S-, -alquilC1-4-NR'R'' y NR'R''; R' y R'' son independientemente alquilo C1-6 o H; n es de 1 a 5; * indica un primer centro quiral; y @ indica un segundo centro quiral. Reivindicacion 5: Un compuesto de formula (2), y sales o derivados farmacéuticamente aceptables del mismo, donde: R1 y R6, R7 y R8 se seleccionan independientemente entre H, -alquiloC1-6, arilo, -cicloalquiloC3-8, -alqueniloC2-6, -cicloalquenilo C5-8, - (CH2)ncicloalquiloC3-9, -alcoxiC1-6, -O-arilo, heterociclo, -SO2, OH, halo, -CF3, -CHF2, -CH2F, OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, -CON(H)alquiloC1-6, -CON(alquiloC1-6)2, hidroxi-alquiloC1-6, -alcoxiC1-4-alquiloC1-6, -SCF3, -alquilC1-6- SO2, -alquilC1-4-S-alquiloC1-4, -alquilC1-4-S-, alquilC1-4-NR'R'' y NR'R'' y donde cada uno de los grupos -alquiloC1-6, arilo, -cicloalqueniloC3-8, -alqueniloC2-8; -cicloalquenilo C5-8, -alcoxiC1-6, arilo, heterociclo puede estar opcionalmente sustituidos con uno o más de los siguientes grupos: -alquiloC1-6, arilo, heterociclo, OH, halo, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, -CON(H)alquiloC1-6, -CON(alquilC1-6)2, hidroxi-alquiloC1-6, -alcoxi C1-6-alquilo C1- 6, -alcoxiC1-6, -SCF3, -alquilC1-6-SO2, -alquilC1-4-S-alquiloC1-4, -alquilC1-4-S-, -alquilC1-4-NR'R'' y NR'R''; R' y R'' son independientemente -alquiloC1-6 o H; n es de 1 a 5; R3 es H o F; R4 es H o F, sin embargo, cuando R3 es F, R4 no es F; R5 es H, halogeno, alquilo C1-6, alcoxi C1-6, -S-alquiloC1-6, -(CH2)n-O-(CH2)n-, -OCF3 o -SCF3; y * indica un primer centro quiral; y @ indica un segundo centro quiral con la condicion de que cuando R1 sea metilo, -O-metilo, -O-etilo, Cl y R3-R8 sea H, entonces * y @ sean (S,R) o (R,S) y además, cuando R1 es -O-metilo y R6-R8 son H, -O-metilo, Cl o metilo entonces * y @ son (S,R) o (R,S). Reivindicacion 9: Un compuesto de formula (1), y sales o derivados farmacéutica y/o veterinariamente aceptables del mismo, donde: A es O; Z es heteroarilo no fenilo seleccionado entre piridina, furano, tiofeno, naftaleno, naftiridina, pirazol, pirazina, pirimidina, tiazol, oxazol, isoxazol, triazol, tetrazol; o un anillo de fenilo condensado con un heterociclo que contiene N, O o S; donde cada uno de los heteroarilo puede estar opcionalmente sustituido con uno o más de los sustituyentes seleccionados independientemente entre heterociclo, -cicloalquiloC3-8, fenilo, -alqueniloC2-8, - cicloalqueniloC5-8, -(CH2)ncicloalquiloC3-9, -cicloalquiloC5-9 condensado, arilo, H, -SCF3, hidroxi-alquiloC1-6, -alcoxiC1-6, -O-arilo, -(CH2)nS-alquiloC1-6, -alquilC1-6-SO2, -(CH2)nSO2-alquiloC1-6, -alquilC1-6-S-, -alquilC1-4-NR'R'' o NR'R'', donde cualquiera de los grupos anteriores está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre -alquiloC1-6, -cicloalquiloC3-8, -alcoxiC1-6, arilo sustituido o no sustituido, heterociclo, OH, halo, -CF3, -CHF2, - CH2F, -OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, -CON(H)alquiloC1-6, -CON(alquiloC1-6)2, hidroxi-alquiloC1-6, -SCF3, -alquilC1-6-SO2, -alquilC1-4-S-alquiloC1-4, -alquilC1-4-S-, alquilC1-4-NR'R'' y NR'R''; X es heterociclo, arilo, alquilo C1-8, -alqueniloC2-8, -cicloalquiloC5-8, biciclo benzocndensado, -cicloalquiloC3-8, -(CH2)n-cicloalquiloC3-8, -cicloalquiloC5-9 condensado, H, -SCF3, hidroxi-alquiloC1-6, -alcoxiC1-6, alquiloC1-6, -(CH2)nS-alquiloC1-6, -(CH2)nSO2-alquiloC1-6, donde cada grupo está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre -alquiloC1-6, cicloalquilo C3-8, -alcoxiC1-6, arilo, heterociclo, OH, halo, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -O(CH2)nCF3, -CN, -CONH2, - CON(H)alquiloC1-6, -CON(alquiloC1-6)2, hidroxi-alquiloC1-6, -SCF3, -alquilC1-6-SO2, -alquilC1-4-S-alquiloC1-4, -alquilC1-4-S-, -alquilC1-4-NR'R'', NR'R''; R' y R'' son independientemente alquilo C16 o H; n es de 1 a 5; * indica un primer centro quiral; y @ indica un segundo centro quiral.
ARP050101667A 2004-04-30 2005-04-28 Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central AR049335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56724404P 2004-04-30 2004-04-30

Publications (1)

Publication Number Publication Date
AR049335A1 true AR049335A1 (es) 2006-07-19

Family

ID=34965714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101667A AR049335A1 (es) 2004-04-30 2005-04-28 Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central

Country Status (28)

Country Link
US (1) US7659394B2 (es)
EP (1) EP1745029A1 (es)
JP (2) JP4185154B2 (es)
KR (1) KR100943555B1 (es)
CN (1) CN1950348A (es)
AP (1) AP2006003771A0 (es)
AR (1) AR049335A1 (es)
AU (1) AU2005238296A1 (es)
BR (1) BRPI0510453A (es)
CA (1) CA2564994A1 (es)
CR (1) CR8718A (es)
EA (1) EA200601798A1 (es)
EC (1) ECSP066962A (es)
GE (1) GEP20084550B (es)
GT (1) GT200500097A (es)
IL (1) IL178648A0 (es)
MA (1) MA28555B1 (es)
MX (1) MXPA06012505A (es)
NL (1) NL1028924C2 (es)
NO (1) NO20065456L (es)
PA (1) PA8631301A1 (es)
PE (1) PE20060680A1 (es)
SV (1) SV2006002098A (es)
TN (1) TNSN06348A1 (es)
TW (1) TW200600506A (es)
UY (1) UY28876A1 (es)
WO (1) WO2005105763A1 (es)
ZA (1) ZA200608628B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
CA2641304A1 (en) * 2006-02-01 2007-08-09 Merck & Co., Inc. Potassium channel inhibitors
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
US7531519B2 (en) * 2006-09-21 2009-05-12 Medical And Pharmaceutical Industry Technology And Development Center Polygalatenosides and use thereof as an antidepressant agent
TW200846002A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
TW200846003A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
EP2161998B1 (en) * 2007-06-04 2015-09-02 Intra-Cellular Therapies, Inc. Pyridine derivatives as NET/SERT modulators
JP5405571B2 (ja) * 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
MX2011005089A (es) 2008-11-14 2011-07-29 Theravance Inc Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
US8474529B2 (en) * 2009-04-09 2013-07-02 Regency Technologies Llc Control of concentric tubing direction
AR075988A1 (es) * 2009-04-09 2011-05-11 Lilly Co Eli Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
RU2535669C2 (ru) * 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
JP5714580B2 (ja) 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
EP2390248A1 (en) 2010-05-24 2011-11-30 Faes Farma, S.A. Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
RU2012155839A (ru) 2010-05-24 2014-06-27 Фаэс Фарма, С.А. Производные флуфеноксина для лечения и предупреждения амилоидных патологий
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201206893A (en) * 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP2012207995A (ja) * 2011-03-29 2012-10-25 Univ Of Fukui 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識ｐｅｔ分子イメージングプローブ
EP2745876A1 (en) * 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
EP3270920B1 (en) * 2015-03-20 2020-06-17 Intra-Cellular Therapies, Inc. Organic compounds
HRP20201405T1 (hr) 2016-03-17 2020-11-27 F. Hoffmann - La Roche Ag Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a
BR112022008113A2 (pt) 2019-10-31 2022-07-19 Escape Bio Inc Formas sólidas de um modulador de receptor s1p
WO2025135797A1 (ko) * 2023-12-18 2025-06-26 주식회사 아스트로젠 (s)-빌록사진 또는 이의 염의 개선된 제조 방법

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
GB1260886A (en) * 1969-06-20 1972-01-19 Ici Ltd Process for aryloxymethylmorpholine derivatives
BE759013R (fr) 1969-11-17 1971-05-17 Ici Ltd Derives de la
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4116665A (en) * 1976-04-02 1978-09-26 Eli Lilly And Company Method of regulating the growth of aquatic weeds with pyridine derivatives
DE2715138B2 (de) 1977-04-05 1980-02-07 Forbach Gmbh & Co Kg, 8740 Bad Neustadt Wasserbehälter aus Kunststoff fur einen Heißwasserbereiter
IT1093255B (it) 1978-01-20 1985-07-19 Erba Carlo Spa Derivati fenossialcanolaminici
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
CA1215067A (en) 1982-10-18 1986-12-09 Sudarshan K. Malhotra 2-(6-phenoxy-3-nitro-2-pyridinoxy)-propionate compounds
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US5272167A (en) * 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5750532A (en) * 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
FR2612926B1 (fr) 1987-03-24 1989-06-09 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2653999A1 (fr) 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH04185154A (ja) * 1990-11-20 1992-07-02 Nec Corp 中継台接続制御方式
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5559135A (en) 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
TW375612B (en) 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
WO1997019059A1 (en) 1995-11-17 1997-05-29 Sibia Neurosciences, Inc. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
RU2230740C2 (ru) 1998-03-31 2004-06-20 Акадиа Фармасьютикалз, Инк. Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO1999050262A1 (en) 1998-04-01 1999-10-07 Janssen Pharmaceutica N.V. Pde iv inhibiting pyridine derivatives
CA2340341A1 (en) * 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
TR200101885T2 (tr) * 1998-12-29 2002-01-21 Pharmacia & Upjohn Company Aril eterler hazırlamak için yöntem.
EP1169024B1 (en) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
CA2383466C (en) * 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
EP1246829A1 (en) 1999-12-17 2002-10-09 Ariad Pharmaceuticals, Inc. Novel heterocycles
HRP20020599A2 (en) 2000-01-18 2004-08-31 Pfizer Prod Inc Corticotropin releasing factor antagonists
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
AU2001241142B2 (en) 2000-04-28 2005-09-22 Tanabe Seiyaku Co., Ltd. Cyclic compounds
US20040048860A1 (en) 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
EP1441728A2 (en) 2001-11-01 2004-08-04 Vertex Pharmaceuticals Incorporated Modulators of the cholesterol biosynthetic pathway
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
DE60223718T2 (de) * 2001-12-11 2008-10-30 Eli Lilly And Co., Indianapolis Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ATE400551T1 (de) 2002-01-04 2008-07-15 Neurosearch As Kaliumkanal-modulatoren
US20050009927A1 (en) * 2002-01-23 2005-01-13 Pfizer Inc Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US6962932B2 (en) * 2002-02-15 2005-11-08 Schering Aktiengesellschaft 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
PL223471B1 (pl) * 2002-03-15 2016-10-31 Cypress Bioscience Inc Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
GB0215392D0 (en) 2002-07-03 2002-08-14 Glaxo Group Ltd Chemical compounds
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
CA2495342C (en) 2002-08-15 2008-08-26 Schlumberger Canada Limited Use of distributed temperature sensors during wellbore treatments
EP1534291B1 (en) * 2002-08-23 2008-11-12 Eli Lilly And Company 2-(phenylthiomethyl)- morpholine derivatives for use as selective norepinephrine reuptake inhibitors
US7294623B2 (en) * 2002-08-23 2007-11-13 Eli Lilly And Company Benzyl morpholine derivatives
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
AU2002349613A1 (en) 2002-11-27 2004-06-18 Alim Ivanovich Chabanov Method for developing a high-power helioenergetic plant
JP2004189738A (ja) 2002-11-29 2004-07-08 Nippon Nohyaku Co Ltd 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
WO2004058353A2 (en) 2002-12-24 2004-07-15 Paradigm Therapeutics Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2532349A1 (en) 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
EP1660065A2 (en) 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005020975A2 (en) 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
WO2005066144A1 (en) 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
DE102004005545B4 (de) 2004-02-04 2018-10-31 Siemens Healthcare Gmbh Verbindungsanordnung und Flachbaugruppe
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds

Also Published As

Publication number Publication date
WO2005105763A1 (en) 2005-11-10
BRPI0510453A (pt) 2007-10-30
NL1028924A1 (nl) 2005-11-01
AU2005238296A1 (en) 2005-11-10
ZA200608628B (en) 2009-01-28
CA2564994A1 (en) 2005-11-10
PA8631301A1 (es) 2006-05-16
PE20060680A1 (es) 2006-08-11
KR100943555B1 (ko) 2010-02-22
MXPA06012505A (es) 2006-12-15
UY28876A1 (es) 2005-11-30
JP4185154B2 (ja) 2008-11-26
US7659394B2 (en) 2010-02-09
JP2008019267A (ja) 2008-01-31
JP2007535530A (ja) 2007-12-06
TNSN06348A1 (fr) 2008-02-22
GEP20084550B (en) 2008-11-25
US20050245519A1 (en) 2005-11-03
MA28555B1 (fr) 2007-04-03
TW200600506A (en) 2006-01-01
CN1950348A (zh) 2007-04-18
ECSP066962A (es) 2006-12-20
NL1028924C2 (nl) 2006-04-27
KR20070006881A (ko) 2007-01-11
CR8718A (es) 2007-07-24
EP1745029A1 (en) 2007-01-24
SV2006002098A (es) 2006-02-15
EA200601798A1 (ru) 2007-04-27
NO20065456L (no) 2007-01-04
AP2006003771A0 (en) 2006-10-31
IL178648A0 (en) 2007-02-11
GT200500097A (es) 2005-12-12

Similar Documents

Publication Publication Date Title
AR049335A1 (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
ES2879351T3 (es) Sales de derivados de piperazina obtenidas por adición de ácidos
AR098991A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
AR075051A1 (es) Compuestos antidiabeticos que contienen ftalazina
AR041347A1 (es) Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
CA2971357A1 (en) Amido thiadiazole derivatives as nadph oxidase inhibitors
FI863564A0 (fi) Foerfarande foer framstaellning av heterocykliskt substituerade indoler.
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
JP2018525375A5 (es)
PE20020667A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
AR045536A1 (es) Inhibidores de la fosfodiesterasa tipo -iv
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
CO6220967A2 (es) Compuestos organicos y sus usos
AR064726A1 (es) Inhibidores de rho quinasa
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20120900A1 (es) Compuestos heterociclicos de fenoximetilo
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
PE20190909A1 (es) Derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol ¨3-cinasa delta y gamma
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
BR112019024376A2 (pt) composto de fórmula geral (i), ou sais farmaceuticamente aceitáveis destes, composição farmacêutica e uso dos compostos ou sais farmaceuticamente aceitáveis destes
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure